Urolog. pro Praxi, 2008; 9(3): 120-127

Renal cell carcinoma - current trends

MUDr. Leoš Gronka1, MUDr. Martina Poršová2, MUDr. Ivan Kolombo FEBU3, et al
1 Urologická poradna Městská nemocnice, Turnov
2 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
3 Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha

Renal cell carcinoma (RCC) is the most malignant urological tumour and the incidence of RCC in the Czech Republic is currently highest in the world. Basic treatment modality for localized disease is surgical therapy. In recent years minimally invasive treatment has become an established surgical procedures. Laparoscopy and also daVinci® robot assisted laparoscopy are currently used and for high-risk and polymorbid patients we used for example radiofrequency ablation. Systemic therapy for metastatic RCC with new two antiangiogenics drugs: an oral oxindol tyrosine kinase inhibitor – sunitinib (Sutent®) and with an oral multikinase inhibitor – sorafenib (Nexavar®) is more effective than previous immunotherapy with cytokines. Bone metastases of RCC can lead to debilitating skeletal complicatinons. Zoledronic acid (Zometa®) significantly delays the onset and reduces the incidence of skeletal-related events and demonstrated trends for longer overall survival in these patient populations. This review article summarize new knowledge and current trends for a treatment of RCC.

Keywords: kidney cancer, laparoscopy, daVinci robotic surgery, radiofrequency ablation, sunitinib (Sutent®), sorafenib (Nexavar®), zoledronic acid (Zometa®)

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gronka L, Poršová M, Kolombo I, al E. Renal cell carcinoma - current trends. Urol. praxi. 2008;9(3):120-127.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Vorlíček J, Vaníček J, et al. Diagnostické a léčebné postupy u maligních chorob. Praha: Grada 2003.
    2. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, et al. German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN): Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92(5): 843-846. Go to original source... Go to PubMed...
    3. Babjuk M, Matoušková M, Novák J. Zhoubné nádory ledvinového parenchymu dospělého věku; 37-43, In: Doporučené diagnostické a léčebné postupy u urologických nádorů. Praha: Galén, 2003.
    4. Belej K, Kaplan O. Možnosti CT a MR v zobrazení nádorů močového měchýře. Urolog. pro Praxi 2007; 1: 15-17.
    5. Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30(3): 220-227. Go to original source... Go to PubMed...
    6. Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006; 175 (3 Pt 1): 864-869. Go to original source... Go to PubMed...
    7. Ctvrtlík F, Heřman M, Študent V, Tichá V, Minařík J. Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT. Eur J Radiol 2008; 14 Go to original source...
    8. Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney AM, Kaouk JH, Gill IS. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol 2005; 173(1): 38-41. Go to original source... Go to PubMed...
    9. Dvořáček J. Nádory ledvin. In: Dvořáček J. Urologie praktického lékaře. Praha: ISV, 2000: 129-133.
    10. Eret V, Hora M, Klecka J, Stránský P, Ferda J, Hes O, Urge T. Laparoscopic radical nephrectomy - the cohort of 150 patients. Cas Lek Cesk 2007; 146(10): 758-762. Go to PubMed...
    11. Escudier B, Eisen T, Stadler WM, Szczylik C, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134. Go to original source... Go to PubMed...
    12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, et al. AVOREN Trial investigators: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111. Go to original source... Go to PubMed...
    13. Hafez KS, Fergany AF, Novick AC. Nephron-sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999; 162: 1930-1933. Go to original source... Go to PubMed...
    14. Hanuš M. Místo urologa v koncepci péče o uroonkologicky nemocné. Urolog. pro Praxi 2007; 8(5): 202-204.
    15. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007; 177(3): 862-866. Go to original source... Go to PubMed...
    16. Hora M. Nádory ledvin. Urolog. pro Praxi 2005; 1: 28-30.
    17. Hora M, Klečka J jr., Stránský P, Hes O. Antegrádní provedení miniinvazivní nefroureterektomie (Laparoskopická nefrektomie s následnou endoskopickou excizí ureterovezikální junkce). Čes Urol 2005; 9(2): 29.
    18. Kawaciuk I. Epidemiologie karcinomu ledviny, Urolog. pro Praxi 2005; 6: 248-252.
    19. Kawaciuk I. Prognóza karcinomu ledviny. Praha: Galén, 2005.
    20. Klener P, Abrahámová J. Nádory ledvin. In: Klener P. Klinická onkologie. Praha: Galén a Karolinum, 2002: 435-442.
    21. Kolombo I, Beňo P, Toběrný M, Bartůněk M, Tobiáš J. Naše první zkušenosti s robotickou laparoskopickou pyeloplastikou da Vinci. Urolog. pro Praxi 2007; 2: 80-83.
    22. Kolombo I, Kolombová J, Beňo P, Toběrný M, et al. Mezioborová spolupráce v urologii. Urolog. pro Praxi 2007; 8(6): 262-267.
    23. Kolombo I, Kolombová J, Dvořáček J, Hanuš T, et al. Skeletální postižení v uroonkologii. Praha: Galén, 2005.
    24. Kolombo I, Kolombová J, Vlásek T. Místo bisfosfonátů při skeletálním postižení v uroonkologii. Urolog. pro Praxi 2006; 5: 228-242.
    25. Kolombo I, Kříž R, Janoušková L, Poněšický J, Beňo P, Toběrný M, Černohorský S, Bartůněk M, Tobiáš J, Čech M, Beneš P: Selective embolization and radiofrequency ablation of renal mass in polymorbid and elderly patients - our experience. Eur Urol Meetings 2007; Abstracts of the EAU 7th Central European Meeting 26-27 October 2007, Zagreb, Croatia, Vol 2, Issue 7, Abstract 26.
    26. Kural AR, Demirkesen O, Onal B, Obek C, Tunc B, Onder AU, Yalcin V, Solok V. Outcome of nefronsparing surgery: elective versus imperative indications. Urol Int, 2003; 71: 190-196. Go to original source... Go to PubMed...
    27. Kwon EO, Carver BS, Snyder ME, Russo P. Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours. BJU Int 2007; 99(2): 286-289. Go to original source... Go to PubMed...
    28. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98(5): 962-969. Go to original source... Go to PubMed...
    29. Ljunberg B, Hanbury DC, Kuczyk MA, Mersenburger AS, Mulders PFA, Patard JJ, Sinescu IC, EAU Guidelines on Renal Cell Carcinoma, EAU, Update 2007. Go to original source...
    30. Melichar B. Metastatický karcinom ledviny. In: Dvořáček J, Babjuk M, et al. Onkourologie. Praha: Galén a Karolinum, 2005: p. 56-67.
    31. Morávek P. Nádory ledvin a horních močových cest. Chirurgická terapie. In: Dvořáček J, Babjuk M, et al. Onkourologie. Praha: Galén a Karolinum, 2005: p. 44-56.
    32. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O' Toole T, Boni JP, Dutcher JP. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25(25): 3958-3964. Go to original source... Go to PubMed...
    33. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178(5): 1883-1887. Go to original source... Go to PubMed...
    34. Novick AC, Cambell SC. Renal tumors. In: Walsh PC, Retik AB et al. Cambell´s Urology. 8th ed. Philadelphia: W. B Saubders, 2003, CD-Rom, Vol. 4, Sections Oncology.
    35. Pacovský J, Navrátil P, Broďák M. Odběr ledviny k transplantaci od žijícího dárce. Urolog. pro Praxi, 2006; 1: 15-18.
    36. Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW, Thüroff JW: Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. J Urol 2006; 175(6): 2027-2031. Go to original source... Go to PubMed...
    37. Raman JD, Bensalah K, Bagrodia A, Stern JM, Cadeddu JA. Laboratory and clinical development of single keyhole umbilical nephrectomy. Urology 2007; 70(6): 1039-1042. Go to original source... Go to PubMed...
    38. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8(11): 975-984. Go to original source... Go to PubMed...
    39. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301. Go to original source... Go to PubMed...
    40. Šafařík L, Novák K, Sedláček J, Macek P, Pešl M, Sobotka R, Dvořáček J. Rozvoj laparoskopické operativy dospělých na Urologické klinice 1. LF a VFN v Praze. Čas Lék čes 2007; 146(10): 806-808.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.